MPHR(A): TRANSCRIPTION FACTOR REQUIRED FOR ERYTHROMYCIN RESISTANCE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 调节蛋白MphR（A）最近在合成生物学应用中得到了广泛应用，例如代谢物传感和基因表达的外源控制。 该蛋白通过与起始密码子上游的35 bp DNA操纵子结合来负调节大环内酯2 '-磷酸转移酶I抗性基因（mphA）的表达，并且通过红霉素的存在去抑制。 我们在该项目中的目标是确定红霉素结合和游离Mphr（A）之间的结构差异，以了解如何对其进行工程改造以响应不同的大环内酯类抗生素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The regulatory protein MphR(A) has recently seen extensive use in Synthetic Biological applications such as metabolite sensing and exogenous control of gene expression. This protein negatively regulates the expression of a macrolide 2'-phosphotransferase I resistance gene (mphA) via binding to a 35bp DNA operator upstream of the start codon, and is de-repressed by the presence of erythromycin. Our goal in this project was to determine the difference in structure between the erythromycin bound and free Mphr(A) in order to understand how it might be engineered to respond to different macrolide antibiotics.